✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Clinical Reference

STEP Trial Results

Released: Last reviewed:

STEP-1 through STEP-4 trials established semaglutide's weight-management efficacy. Pivotal STEP-1 (NEJM 2021, PMID 33567185): 14.9% mean weight loss at 2.4 mg / 68 weeks.

Clinical referencePubMed-linked
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Overview

STEP-1 through STEP-4 trials established semaglutide's weight-management efficacy. Pivotal STEP-1 (NEJM 2021, PMID 33567185): 14.9% mean weight loss at 2.4 mg / 68 weeks.

PubMed citations

Related clinical pages

Key facts, checked November 20, 2026

In STEP 1 (NEJM 2021), adults with obesity or overweight and no diabetes lost an average of 14.9% of body weight at 68 weeks on semaglutide 2.4 mg, against 2.4% on placebo. At least 5% weight loss was reached by 86.4% versus 31.5%, at least 10% by 69.1% versus 12.0%, and at least 15% by 50.5% versus 4.9%. Average weight change was −15.3 kg versus −2.6 kg. Later STEP trials tested continued treatment and two-year use. These results come from FDA-approved Wegovy, not compounded semaglutide.